1. Market Research
  2. > Healthcare Market Trends
  3. > The Reality of Market Access in Europe: the role of Health Technology Assessment

The Reality of Market Access in Europe: the role of Health Technology Assessment

  • March 2014
  • -
  • Firstword Pharma
  • -
  • 82 pages

Summary

Table of Contents




Faced with slipping or negligible GDP growth and an economic crisis, Eurozone countries are drilling down into healthcare budgets as a means of controlling expenditure.

From price cuts, tighter reimbursement criteria and greater patient co-payments to the wider use of generics and manufacturer risk-sharing agreements, the largest markets are examining ways to balance the public good with fiscal goals.

Set against that background is Health Technology Assessment (HTA). Widely used as part of the pricing and reimbursement process in Europe, HTA is nevertheless still in the early stages of being coordinated into a system across Europe.

In The Reality of Market Access in Europe: the role of Health Technology Assessment, FirstWord skilfully addresses the issues surrounding HTA, both for its potential to rationalise treatment on economic grounds and as a means to assess the cost effectiveness of new products. Focused on the agencies, procedures and approaches of HTA in the six largest EU markets, the report provides a coherent and current overview of pricing and reimbursement, controversies over issues like rule-making and individual product cases, and what the future of HTA will look like.












Key Benefits

Attitudes to drug reimbursement have been shaped by economics. In The Reality of Market Access in Europe: the role of Health Technology Assessment, you will:


Understand how economic uncertainties are affecting pharmaceutical reimbursement spending
Gain insight into how HTA has become more formalised and transparent in recent years
Know which countries have the most advanced HTA systems and why
Understand how HTA can provide a more certain route to market, and raise the bar for new drugs entering the market

Filled with compelling and important insights into an evolving market, the report offers:

Up-to-date charts and figures, translated European sources and insights into the HTA process
A look at different approaches—and outcomes—in the top six EU markets
Insight on how HTA affects market access for new drugs, and the additional information HTA agencies demand
Insight into moves to co-ordinate HTA approaches across the EU
Discussion of how health budgets are affected by the EU’s current economic reality


Key Questions Answered

How have national attitudes towards drug reimbursement been shaped by economic realities?
Which countries have the most advanced HTA systems and which countries are following the lead?
How have HTA reforms created market hurdles?
What changes in information provision now affect manufacturers?
How can HTA increase access to new drugs?
How have coordinating moves at EU level affected the conduct of the HTA process?







Key facts

Despite worsening economic circumstances, health spending accounts for a greater proportion of the GDP in France, Germany, Italy, Poland, Spain and the United Kingdom than in 2009.
Expensive medicines are more widely distributed in European countries, along with specific high-cost therapy areas such as cancer.
Although established in 2006, the EUnetHTA is still in the early stages of harmonising HTA approaches across the Eurozone.


Content Highlights
Pharmaceutical manufacturers are increasingly faced with changing rules and practices on reimbursement. In this report, you will discover:

The role of the key governing agencies and how they operate in six key European markets
How the downward pressure of cost containment is being met with the upward push from patient groups for the latest products
The most up-to-date and expertly translated charts and data



Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2017 World Infectious Disease Testing Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales and Volume Forecasts for 100 Microbiology Tests, Supplier Shares, Competitive Strategies, Instrumentation, Technologies, Opportunities

2017 World Infectious Disease Testing Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales and Volume Forecasts for 100 Microbiology Tests, Supplier Shares, Competitive Strategies, Instrumentation, Technologies, Opportunities

  • $ 59500
  • Industry report
  • January 2017
  • by Venture Planning Group

This unique 68-country survey from VPGMarketResearch.com provides data and analysis not available from any other published source. The survey is designed to assist diagnostics industry executives, as well ...

2017 World Automated Microbiology Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Volume and Sales Forecasts for 100 Molecular Diagnostic Tests, Supplier Shares, Competitive Strategies, Instrumentation, Technologies

2017 World Automated Microbiology Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Volume and Sales Forecasts for 100 Molecular Diagnostic Tests, Supplier Shares, Competitive Strategies, Instrumentation, Technologies

  • $ 52500
  • Industry report
  • January 2017
  • by Venture Planning Group

This new 75-country survey from VPGMarketResearch.com provides granular data and analysis not available from any other published source. The survey is designed to help current suppliers and potential market ...

2017 Europe Diagnostics Market Forecasts: Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2017 Europe Diagnostics Market Forecasts: Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

  • $ 47500
  • Industry report
  • January 2017
  • by Venture Planning Group

This new report from VPGMarketResearch.com provides granular analysis of the Europe diagnostic testing market, including Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.